Melanoma has “traditionally” been the tumor that is most vulnerable to immunotherapeutic strategies, since the employment of high-dose recombinant interleukin 2 (IL-2) in the 1980s, and it is also quite sensitive to ICIs [7]. This evidence concerns the gene IL2 and melanoma.